JP2024527288A5 - - Google Patents

Info

Publication number
JP2024527288A5
JP2024527288A5 JP2023579158A JP2023579158A JP2024527288A5 JP 2024527288 A5 JP2024527288 A5 JP 2024527288A5 JP 2023579158 A JP2023579158 A JP 2023579158A JP 2023579158 A JP2023579158 A JP 2023579158A JP 2024527288 A5 JP2024527288 A5 JP 2024527288A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
chain variable
ccr8
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023579158A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527288A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/101000 external-priority patent/WO2022268192A1/en
Publication of JP2024527288A publication Critical patent/JP2024527288A/ja
Publication of JP2024527288A5 publication Critical patent/JP2024527288A5/ja
Pending legal-status Critical Current

Links

JP2023579158A 2021-06-25 2022-06-24 抗ccr8抗体及びその使用 Pending JP2024527288A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/102324 2021-06-25
CNPCT/CN2021/102324 2021-06-25
CNPCT/CN2022/092803 2022-05-13
CNPCT/CN2022/092803 2022-05-13
PCT/CN2022/101000 WO2022268192A1 (en) 2021-06-25 2022-06-24 Anti-ccr8 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2024527288A JP2024527288A (ja) 2024-07-24
JP2024527288A5 true JP2024527288A5 (enExample) 2025-07-02

Family

ID=84544143

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023579158A Pending JP2024527288A (ja) 2021-06-25 2022-06-24 抗ccr8抗体及びその使用

Country Status (8)

Country Link
US (1) US20240352134A1 (enExample)
EP (1) EP4359442A4 (enExample)
JP (1) JP2024527288A (enExample)
KR (1) KR20240025013A (enExample)
CN (1) CN117616046A (enExample)
AU (1) AU2022298850B2 (enExample)
TW (1) TW202325732A (enExample)
WO (1) WO2022268192A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
WO2024248037A1 (ja) 2023-05-30 2024-12-05 塩野義製薬株式会社 Ccr8を抗原として認識する二重特異性抗体
CN117285627B (zh) * 2023-09-06 2024-06-14 百济神州(上海)生物科技有限公司 抗ccr8抗体及其用途
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗fap-light融合蛋白及其用途
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof
CN119080936B (zh) * 2024-10-24 2025-05-23 百济神州(上海)生物科技有限公司 抗ccr8抗体及其用途
CN122036947A (zh) * 2024-11-11 2026-05-15 广东菲鹏制药股份有限公司 抗ccr8抗体或其抗原结合片段及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044756A2 (en) * 2005-10-11 2007-04-19 Icos Corporation Monoclonal antibodies recognizing human ccr8
CN110835371A (zh) * 2018-08-19 2020-02-25 普米斯生物技术(苏州)有限公司 抗ccr8单克隆抗体及其应用
BR112021011431A2 (pt) * 2018-12-27 2021-11-23 Univ Osaka Anticorpo monoclonal ou um fragmento de anticorpo do mesmo que se liga ao ccr8, seu uso, bem como composição farmacêutica, polinucleotídeo, vetor de expressão e kit
AU2021244200A1 (en) * 2020-03-23 2022-11-24 Bristol-Myers Squibb Company Anti-CCR8 antibodies for treating cancer

Similar Documents

Publication Publication Date Title
JP2025111463A5 (enExample)
US10947314B2 (en) Antibodies targeting b-cell maturation antigen and methods of use
JP2022177090A5 (enExample)
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
JP2020508655A5 (enExample)
JP2020514277A5 (enExample)
JP2021522162A5 (enExample)
RU2019141289A (ru) АНТИ-SIRPα АНТИТЕЛА
CN115605511A (zh) 抗tigit的抗体、其制备方法和应用
RU2021110369A (ru) Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген
JP2020533311A5 (ja) NKG2D、CD16およびNectin4に結合するタンパク質
RU2014122990A (ru) Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas
RU2012112829A (ru) Анти-gitr-антитела
JP2021508707A5 (enExample)
JP2020502233A5 (enExample)
JP2020515277A5 (enExample)
JP2022549172A5 (enExample)
JP2023525695A5 (enExample)
JP2024024114A5 (enExample)
JP2021511387A5 (enExample)
JP2025511289A5 (enExample)
JP2021512604A5 (enExample)
JP2020513759A5 (enExample)
RU2019121106A (ru) Иммунотерапия с применением антител, связывающих белок 1 программируемой смерти клеток (pd-1)
JP2021518748A5 (enExample)